Hutchmed China Limited Adr (HCM)

개요 뉴스 가격 이력 옵션 체인 토론 예측

Relative Volume:

Hutchmed China Limited Adr Stock (HCM) Company Profile

Hutchmed China Limited Adr

Healthcare (1069)

최신 SEC 제출 서류

HCM's Discussions on Twitter

Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
HCM Hutchmed China Limited Adr	12.82	2.23B	549.97M	458.86M	-89.06M	2.6236
TAK Takeda Pharmaceutical Co Adr	18.26	58.31B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	37.09	43.22B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.19	40.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.97	30.15B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	497.11	21.32B	3.17B	1.29B	1.01B	27.09

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-09-22	다운그레이드	Morgan Stanley	Equal-Weight → Underweight
2025-05-13	다운그레이드	HSBC Securities	Buy → Hold
2023-11-24	업그레이드	Deutsche Bank	Hold → Buy
2022-05-04	다운그레이드	Deutsche Bank	Buy → Hold
2021-09-22	다운그레이드	Goldman	Buy → Neutral
2021-08-03	개시	Jefferies	Buy
2020-10-02	개시	Deutsche Bank	Buy
2020-03-13	개시	Cantor Fitzgerald	Overweight
2020-02-20	개시	Goldman	Buy
2019-11-19	개시	CLSA	Buy
2019-10-23	재확인	BofA/Merrill	Buy
2019-07-05	개시	Macquarie	Outperform

Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스

Hutchmed China Limited Adr (HCM) 재무 분석

Hutchmed China Limited Adr (HCM)

Hutchmed China Limited Adr Stock (HCM) Company Profile

Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스

symbol__ Stock Quote Price and Forecast - CNN

Trinity Delta Lighthouse: HUTCHMED - Vox Markets

Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research

China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy - BioSpectrum Asia

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - Yahoo Finance

HUTCHMED (NASDAQ:HCM) Shares Gap UpWhat's Next? - MarketBeat

Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion - finance.biggo.com

Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com

GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy - GlobeNewswire

Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research

HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseHere's What Happened - MarketBeat

Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research

HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat

HUTCHMED’s SANOVO Phase III Trial Demonstrates Significant PFS Advantage for ORPATHYS Plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer - Kalkine Media

HUTCHMED (HCM) lung cancer combo tops China Phase III trial - Stock Titan

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China - Barchart.com

HUTCHMED (China) LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response - Stock Titan

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat

HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat

HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeShould You Buy? - MarketBeat

AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success - TradingView

HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case - Stock Titan

HUTCHMED (HCM) lung cancer combo extends survival after TAGRISSO - Stock Titan

ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView

HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusDelta Hedging - vinanet.vn

HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving AverageHere's Why - marketbeat.com

REGHutchmed China LtdHUTCHMED Reports 2026 Interim Results - TradingView

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth - finance.yahoo.com

A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView

HUTCHMED (NASDAQ:HCM) Stock Price Down 6%Here's Why - MarketBeat

Sea Limited Sponsored ADR (SE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance

Price to sales forward of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView

HCM Stock Price, Quote & Chart - ChartMill

Sea Limited Sponsored ADR (SE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer - Stock Titan

HUTCHMED Announces NMPA Approval for ORPATHYS® for the - GlobeNewswire

Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView

HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts - Stock Titan

HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire

HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan

HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView

HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView

H7T1 Forecast — Price Target — Prediction for 2027 - TradingView

0J7G Forecast — Price Target — Prediction for 2027 - TradingView

HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LSX:A2AF74) - TradingView

HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (NASDAQ:HCM) - TradingView

Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM) - Stock Titan

RCSHutchmed China LtdHUTCHMED Highlights Phase II Data at ESMO - TradingView

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib - GlobeNewswire

Hutchmed China Limited Adr (HCM) 재무 분석

매출

순이익

현금흐름

주당 순 이익

HCM과 유사한 종목